Plasma cell morphology in multiple myeloma and related disorders.
Ribourtout B et al. Morphologie. 2015 Apr 18. pii: S1286-0115(15)00021-1. doi: 10.1016/j.morpho.2015.02.001. [Epub ahead of print].

Proteomic Analysis for Finding Serum Pathogenic Factors and Potential Biomarkers in Multiple Myeloma.
Zhang HT et al. Chin Med J (Engl). 2015 20th Apr;128(8):1108-1113. doi: 10.4103/0366-6999.155112.

Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma.
Cho Y et al. Acta Haematol. 2015 Apr 3;134(1):25-31. [Epub ahead of print].

Autophagic Markers BECLIN 1 and LC3 Are Associated with Prognosis of Multiple Myeloma.
Jung G et al. Acta Haematol. 2015 Apr 3;134(1):17-24. [Epub ahead of print].

Screening whole spine Magnetic Resonance Imaging (MRI) in multiple myeloma.
Wight J et al. Intern Med J. 2015 Apr 14. doi: 10.1111/imj.12789. [Epub ahead of print].

The prognostic impact of multiparameter flow cytometry immunophenotyping and cytogenetic aberrancies in patients with multiple myeloma.
Guo J et al. Hematology. 2015 Apr 10. [Epub ahead of print].

High incidence of intact immunoglobulin or fragments thereof in urine of patients with multiple myeloma.
Kraj M et al. Leuk Lymphoma. 2015 Apr 10:1-19. [Epub ahead of print].

Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities.
Song MK et al. Acta Haematol. 2015;134(1):7-16. doi: 10.1159/000370235. Epub 2015 Mar 28.

Improvement of diagnostic confidence for detection of multiple myeloma involvement of the ribs by a new CT software generating rib unfolded images: Comparison with 5- and 1-mm axial images.
Homann G et al. Skeletal Radiol. 2015 Apr 2. [Epub ahead of print].

18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study.
Fonti R et al. Clin Nucl Med. 2015 Apr;40(4):303-8. doi: 10.1097/RLU.0000000000000696.

18F-FDG PET increases visibility of bone lesions in relapsed multiple myeloma: is this hypoxia-driven?
de Waal EG et al. Clin Nucl Med. 2015 Apr;40(4):291-6. doi: 10.1097/RLU.0000000000000629.